mitoxantrone has been researched along with Chemical and Drug Induced Liver Injury in 16 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient with breast cancer developed severe asthenia, accompanied with progressively increasing transaminases, during adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and 5-fluorouracil)." | 8.81 | Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. ( Bogers, J; Schrijvers, D; van den Brande, J; van Marck, E; van Outryve, S; Vermorken, JB; Wilmes, P, 2002) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 7.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 6.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes." | 5.07 | Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993) |
| "A patient with breast cancer developed severe asthenia, accompanied with progressively increasing transaminases, during adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and 5-fluorouracil)." | 4.81 | Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. ( Bogers, J; Schrijvers, D; van den Brande, J; van Marck, E; van Outryve, S; Vermorken, JB; Wilmes, P, 2002) |
| "A 44-year-old white woman with primary progressive MS receiving a multidrug of PO baclofen 75 mg/d, PO piracetam 3 g/d, and IV mitoxantrone 10 mg administered once a month presented to the Multiple Sclerosis Center, University of Catania, Catania, Italy." | 3.75 | Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis. ( Caruso, A; Neri, S; Patti, F; Vecchio, R, 2009) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 3.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established." | 2.77 | Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. ( Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C, 2012) |
| " However, some trials showed that increasing the dosage of anthracyclines within induction therapy improved treatment outcome substantially." | 2.70 | Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. ( Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H, 2002) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 2.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "Mitoxantrone (MTX) is an antineoplastic agent that can induce hepato- and haematotoxicity." | 1.40 | Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. ( Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Palmeira, C; Remião, F; Rossato, LG; Santos-Silva, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 2 |
| Chen, M | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Rossato, LG | 1 |
| Costa, VM | 1 |
| Dallegrave, E | 1 |
| Arbo, M | 1 |
| Dinis-Oliveira, RJ | 1 |
| Santos-Silva, A | 1 |
| Duarte, JA | 1 |
| de Lourdes Bastos, M | 1 |
| Palmeira, C | 1 |
| Remião, F | 1 |
| Caruso, A | 1 |
| Vecchio, R | 1 |
| Patti, F | 1 |
| Neri, S | 1 |
| McLaughlin, B | 1 |
| Im, A | 1 |
| Raptis, A | 1 |
| Agha, M | 1 |
| Hou, JZ | 1 |
| Redner, R | 1 |
| Duggal, S | 1 |
| Lin, Y | 1 |
| Smith, C | 1 |
| Boyiadzis, M | 1 |
| Schaich, M | 1 |
| Illmer, T | 1 |
| Aulitzky, W | 1 |
| Bodenstein, H | 1 |
| Clemens, M | 1 |
| Neubauer, A | 1 |
| Repp, R | 1 |
| Schäkel, U | 1 |
| Soucek, S | 1 |
| Wandt, H | 1 |
| Ehninger, G | 1 |
| van Outryve, S | 1 |
| Schrijvers, D | 1 |
| van den Brande, J | 1 |
| Wilmes, P | 1 |
| Bogers, J | 1 |
| van Marck, E | 1 |
| Vermorken, JB | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Avilés, A | 1 |
| Guzmán, R | 1 |
| Talavera, A | 1 |
| García, EL | 1 |
| Díaz-Maqueo, JC | 1 |
| Feldman, EJ | 1 |
| Alberts, DS | 1 |
| Arlin, Z | 1 |
| Ahmed, T | 1 |
| Mittelman, A | 1 |
| Baskind, P | 1 |
| Peng, YM | 1 |
| Baier, M | 1 |
| Plezia, P | 1 |
| Hirvikoski, PP | 1 |
| Kumpulainen, EJ | 1 |
| Johansson, RT | 1 |
| Johnston, LJ | 1 |
| Stockerl-Goldstein, KE | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Hoppe, RT | 1 |
| Blume, KG | 1 |
| Horning, SJ | 1 |
| Bennett, JM | 1 |
| Young, MS | 1 |
| Liesveld, JL | 1 |
| Paietta, E | 1 |
| Miller, KB | 1 |
| Lazarus, HM | 1 |
| Marsh, RD | 1 |
| Friedenberg, WR | 1 |
| Saba, HT | 1 |
| Hayes, FA | 1 |
| Dewald, GW | 1 |
| Hiddemann, W | 1 |
| Rowe, JM | 1 |
| Vredenburgh, JJ | 1 |
| McIntyre, OR | 1 |
| Cornwell, GG | 1 |
| Ball, ED | 1 |
| Cornell, CJ | 1 |
| Mills, LE | 1 |
| O'Donnell, JF | 1 |
| Paciucci, PA | 1 |
| Sklarin, NT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver In | 2002 |
6 trials available for mitoxantrone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2012 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 2002 |
Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD).
Topics: Actuarial Analysis; Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1993 |
Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Topics: Acetyltransferases; Adult; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Com | 1997 |
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bon | 2001 |
8 other studies available for mitoxantrone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study.
Topics: Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Hematologic Diseases; Leukoc | 2014 |
Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis.
Topics: Administration, Oral; Adult; Baclofen; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis; | 2009 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hema | 1988 |
Mitoxantrone and hepatic toxicity.
Topics: Chemical and Drug Induced Liver Injury; Humans; Mitoxantrone | 1986 |